Navigation Links
Biocept Launches Noninvasive Prenatal Rh(D) Diagnostic at Annual ACOG Scientific Meeting
Date:5/5/2008

SAN DIEGO, May 5 /PRNewswire/ -- Biocept, an emerging leader in biotechnology, will launch I.D. Rh(D), the first in a series of noninvasive prenatal diagnostic tests that can be performed with a simple maternal blood sample, at the Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, May 3-7 in New Orleans.

The I.D.Rh(D) test diagnoses the Rh(D) status of a fetus in an Rh(D) negative pregnancy, and can be performed as early as ten weeks of gestation. The test isolates fetal DNA circulating in the mother's whole blood, using Biocept's proprietary I.D. (Isolating Fetal DNA) platform technology (U.S. patents pending). The fetal DNA is analyzed in Biocept's CLIA-accredited clinical laboratory to determine Rh(D) genotype. Similar noninvasive tests have been available routinely in some countries outside the US.

Each year, approximately 460,000 Rh(D) negative women in the United States become pregnant. If their partners are Rh(D) positive, which they are in approximately 89% of cases, these women risk carrying a fetus that is also Rh(D) positive. When this occurs, the woman may develop antibodies that attack fetal red blood cells, leading to problems ranging from fetal anemia and jaundice to cerebral palsy, mental retardation, and even death.

Until now, the only tests available to definitively diagnose fetal Rh(D) genotype required invasive procedures such as amniocentesis or chorionic villus sampling (CVS), which carry their own risks to the fetus. For this reason, physicians have routinely administered anti-D immune globulin injections, a human blood product, to all Rh(D) negative women at 28-29 weeks of gestation.

"The I.D.Rh(D) test marks the beginning of a new era in definitive noninvasive prenatal testing," said Joe Leigh Simpson, M.D., Executive Associate Dean for Academic Affairs at Florida International University College of Medicine. "I.D.Rh(D) offers physicians and their patients a noninvasive diagnostic alternative."

I.D.Rh(D) is the only fetal Rh(D) diagnostic that identifies fetal DNA in maternal blood in all cases in which a diagnosis can be delivered-whether the fetus is male or female, Rh(D) negative or positive. This eliminates the uncertainty that can occur with other tests in which an Rh(D) negative female fetus cannot be definitively identified from the maternal blood sample.

"We believe I.D.Rh(D) represents a personalized approach to patient care," said Philip Cotter, Ph.D., Biocept's vice president and director of clinical laboratories. "It provides peace of mind to all Rh(D) negative patients early in pregnancy, and enables appropriate treatment of only those patients who require it."

"The test is the first of several noninvasive prenatal diagnostics developed by Biocept," Cotter said. "It is based on the I.D. (Isolating Fetal DNA) platform technology, a novel and proprietary approach to diagnostics developed in our laboratories."

About Biocept

Biocept, an emerging biotechnology leader, engineers novel solutions that provide the foundation for a new class of diagnostic assays. Biocept is based in San Diego, California, a major center for academic and industrial life sciences research. Founded in 1997, the company is privately held and draws on a scientific team rich in experience in life science. Its CLIA-accredited clinical laboratory is accredited by the College of American Pathologists and holds licenses in California and other states as required.


'/>"/>
SOURCE Biocept
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. Novozymes Launches Enzyme to Reduce Acrylamide in Food
3. Enova Medical Launches Exos Corporation
4. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
5. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
6. ThirdBiotech Networking Group Launches
7. BioReliance Launches Next-Generation Genotoxicity Screening Service
8. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
9. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
10. Kingfisher Healthcare Launches Breakthrough Product in Europe
11. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure ... at home or in healthcare facilities during periods of rest. A lightweight, non-invasive ...
(Date:2/23/2017)... , Feb. 23, 2017  Capricor Therapeutics, Inc. (NASDAQ: ... other medical conditions, today announced that Linda Marbán, Ph.D, president ... upcoming investor conferences: Cowen and Company ... 10:00 am ET Boston, MA ... at 9:00 am PT (12:00 pm ET) Dana ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... is has acquired Kendall Research Systems, LLC (KRS) clinical development program. ... develops neural interface technology for research and clinical applications. The terms of the ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... discovery and development of precision treatments for neurodegenerative diseases, today announced it has ... the ProMIS approach.” This is one of a series of commentaries from ProMIS’s ...
Breaking Biology Technology:
(Date:2/8/2017)... The biometrics market has reached a ... organizations, desires to better authenticate or identify users ... challenge questions), biometrics is quickly working its way ... is driven by use cases, though there traditionally ... uses cases, with consumer-facing use cases encompassing authentication, ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
Breaking Biology News(10 mins):